Roche later made changes to the trial design, although the company said overall results support further testing.

The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...

An Alzheimer’s drug from Roche cleared a protein that’s a hallmark of the disease from patients’ brains, suggesting the drug ...

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Roche revealed early-stage data for a new Alzheimer’s program on Wednesday as it seeks to jump back into a field littered ...

Under the terms of the agreement, Roche will pay Dyno Therapeutics $50m upfront, along with additional payments during the ...

Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...